Vorasidenib, a new drug, has performed well in prolonging progression-free survival for patients diagnosed with a subtype of glioma. Patients taking Vorasidenib could avoid disease progression for nearly 17 months, according to an international study. The study was conducted to determine whether a cancer mutation inhibitor, Vorasidenib, has the potential to suppress the growth of gliomas. The results showed that the drug target was met in almost three-quarters of patients, offering new hope for treatment. Glioma, a type of brain cancer, occurs in cells known as glial cells and is notorious for its rapid progression and low survival rate.
Today: December 2, 2023